Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts remain broadly positive: Brainsway has a “Moderate Buy” consensus from seven analysts, with six Buys and one Hold. The average 12-month price target is $16.95, while BTIG recently raised its target to $20.
• Strong operating momentum: The company reported record quarterly revenue of approximately $17.1 million, up 35% year over year, and raised its 2026 revenue outlook to $68 million–$70 million.
• Shares are trading near their annual high: BWAY opened at $16.47 and recently reached a 52-week high of $17.40. Institutional investors and hedge funds own about 30.11% of the stock, though Zacks downgraded the shares from “strong buy” to “hold.”

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report) have earned an average rating of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $16.95.

Several brokerages have recently weighed in on BWAY. Zacks Research downgraded shares of Brainsway from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Brainsway in a research report on Friday, July 17th. BTIG Research upped their price objective on Brainsway from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Brainsway in a research report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Brainsway from a "hold" rating to a "buy" rating in a research note on Sunday, August 2nd.

Institutional Investors Weigh In On Brainsway

Several hedge funds have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Brainsway in the 1st quarter valued at $40,000. Ballast Advisors LLC purchased a new position in Brainsway during the 1st quarter worth $55,000. Raymond James Financial Inc. acquired a new stake in shares of Brainsway in the 2nd quarter worth $85,000. Bank of America Corp DE acquired a new stake in shares of Brainsway in the 3rd quarter worth $107,000. Finally, Royal Bank of Canada boosted its holdings in shares of Brainsway by 1,145.9% in the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company's stock valued at $160,000 after acquiring an additional 7,735 shares in the last quarter. 30.11% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Brainsway

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Strong Q2 performance: BrainsWay reported adjusted EPS of $0.14, beating the $0.10 consensus estimate, while revenue rose 35% year over year to a record $17.1 million, above expectations of $16.54 million. The company also reported a 15.68% net margin and 12.28% return on equity. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Raised full-year outlook: Management forecast 2026 revenue of $68 million to $70 million, modestly above the $67.8 million analyst consensus. The improved outlook reinforces expectations for continued growth in BrainsWay’s transcranial magnetic stimulation business. BrainsWay earnings report
• Positive Sentiment: Analysts raised targets: BTIG Research increased its price target from $18 to $20 and maintained a Buy rating. Ladenburg Thalmann also raised its target from $18 to $18.80 and assigned a Buy rating, indicating further potential upside from recent trading levels. BTIG raises BrainsWay price target
• Neutral Sentiment: Momentum near a new high: BWAY recently reached a new 1-year high following the earnings beat, reflecting strong momentum but also potentially increasing profit-taking risk after the rally. Brainsway sets new 1-year high
• Negative Sentiment: Rating downgrade: Zacks Research cut BrainsWay from “strong buy” to “hold,” providing a counterweight to the favorable earnings news and other analysts’ target increases. Zacks downgrade of BrainsWay

Brainsway Price Performance

BWAY stock opened at $16.47 on Friday. The company has a market cap of $660.94 million, a price-to-earnings ratio of 37.43 and a beta of 1.24. The company has a fifty day moving average price of $15.13 and a 200 day moving average price of $14.36. Brainsway has a 12 month low of $6.26 and a 12 month high of $17.40.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Brainsway had a return on equity of 13.01% and a net margin of 15.65%.The business had revenue of $17.11 million for the quarter, compared to analysts' expectations of $16.54 million. As a group, analysts anticipate that Brainsway will post 0.33 earnings per share for the current year.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source